1 / 77

Structure and function of Serotonin Transporter

Structure and function of Serotonin Transporter. Erice, April 9, 2002. Gary Rudnick Department of Pharmacology Yale University. +. K. Cl -. Na +. +. -. H +. NT. NT. Na +. H +. ATP. Na +. K +. Stoichiometry Bioenergetics of ion coupling Drug interactions Structure

kamea
Download Presentation

Structure and function of Serotonin Transporter

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Structure and function of Serotonin Transporter Erice, April 9, 2002 Gary Rudnick Department of Pharmacology Yale University

  2. + K Cl- Na+ + - H+ NT NT Na+ H+ ATP Na+ K+

  3. Stoichiometry Bioenergetics of ion coupling Drug interactions Structure Binding site Conformational changes Regulation

  4. Na+ SCN- Cl- 5-HT KPi

  5. Curt Keller Hannah Glomska Jie-Guang Chen Susan Liu-Chen Yan Ni Fusun Kilic Andreas Androutsellis-Theotokis Yuan-Wei Zhang Pam Nelson Jane Talvenheimo Susan Keyes Steve Wall Howard Gu Megan Stephan Marisa Chen Yoel Smicun Scott Campbell Dennis Murphy

  6. Stoichiometry and ion coupling

  7. NaClout KPiin gramicidin No gradient (NaCl in=out)

  8. For A-B symport (co-transport): at equilibrium and

  9. + + + - - V + - - + - + - - + - + D H+ TPMP+ K+

  10. + GABA, Proline NE+ 5-HT + 2 Na + + Na Na - - - Cl Cl Cl + K DA, Betaine, Taurine... Glutamic acid Glycine + 2 or 3 Na+ ? Na - + - 3 Na Cl Cl + K + ? K

  11. Drug Interactions

  12. C H 3 N H 2 N H C l C H 3 N C l A m p h e t a m i n e S e r t r a l i n e N H I m i p r a m i n e 2 N H C H C H 3 3 C H N H O 3 F C O 3 M D M A O Fluoxetine N H 2 H O C H 3 C H 3 N O N N O O C H 3 O C H 3 S e r o t o n i n ( 5 - H T ) O - C I T b O C o c a i n e I

  13. Dilution Imipramine control 5-HT + Imip. 5-HT in 5-HT Time

  14. C H 3 N H 2 N H C l C H 3 N C l A m p h e t a m i n e S e r t r a l i n e N H I m i p r a m i n e 2 N H C H C H 3 3 C H N H O 3 F C O 3 M D M A O Fluoxetine N H 2 H O C H 3 C H 3 N O N O N O C H 3 O C H 3 S e r o t o n i n ( 5 - H T ) O - C I T b O C o c a i n e I

  15. +PCA +PCA

  16. NaCl 5-HT+ To NaCl 5-HT+ Ti NaCl 5-HT+ NaCl 5-HT+ Ti To K+ K+ Ti To K+ K+

  17. NaCl MDMA+ SERT MDMA+ ADP ATP K+ H+ H+ H+ MDMA+ MDMA MDMA MDMA

  18. in in in K+ 5-HT+ - Cl - Na+ Cl- Cl- (or H+) Na+ out out out in Mechanism of serotonin in 5-HT+ transport. Coupling to Cl- K+ Na+ sodium, chloride and (or H+) out out potassium gradients in in in 5-HT+ Cl- Cl- out out out

  19. Structure

  20. N T W T T G I N W L D Q N A F S H Y N N C T T S C E x t e r i o r T S R H L V D Y A K T S L F A G P K E V N L P W Q P E Y A E W F I S P V S Q H L L V V K L Q R G D L F S Q D F L R Y E Q C I Y L T K I N E T L R N G N Y W L S Q G D T Y L S L P A Y R I L L E A L G G G T Q G M F E Y P E V G T V V Y Y E P Y P R A H G A L I L G A P I A S T S A W S A W W A M W A T V T M F W A N Q Y G S L G D L I L M I L G I R T P A F N L P I T L V V L A A S G P A T L V L L L V A C L Y S N C T L G S Q L I D T T Y I F Y V G T I I V I F Y V I C S L F V F A M F S L V L I V F A L Y A A A F I L G V C S I L G I I M F G I T L I F F I I Y T S Y S I E G L V G F F V V S P V A P G P S F A I F V F V G V S L I L I Y S T I I F A I P L M I F T C A L G V A F L L C S M I T V V S V I I I C V P L F W W T A W N F W T W F L C L V Y Y V Y A Y I G M V I F G R D L S I A I W M Y T S G F K E R K Y V K L G D T E I W W V L R Q N I A K G G S T L L R F G S K K T V T G E G P A K C G P F K F Q F S R T A T T T I A T D A L S V S A N E E P I P R G Q A Y Q L R I E K W N I D F Y C I R N C K H G E I V I D S G S D R L H K K H T L P K I T S M E E C T E A E S T A N P G E D P S M R P C I E G Q G F V W C I P I T V E S E I D E A T L A V C T S E A R P D N G S S A P Q V T A I N D M S T R I Y L N G L G P N V V V S G L Q K Q K C y t o p l a s m

  21. Exterior C109 Cytoplasm

  22. O N H H N O O S C C H H C N S C H 2 ( C H ) S 3 2 H 2 4 O N - B i o t i n y l a m i n o m e t h y l m e t h a n e t h i o s u l f o n a t e ( M T S E A - B i o t i n ) O O N a O S N H H N 3 O O ( C H ) ( C H ) ( C H ) C N O S S N C 2 4 2 2 2 2 S O N H S - S S - B i o t i n

  23. K399 Exterior K314 L406 Q111 R194 L564 V310 C109 K319 K243 T490 V489 H571 Cytoplasm

  24. Exterior Cytoplasm

  25. Res-FLAG Sens-myc C109A I172C Anti-FLAG 64 kD Anti-myc F L A G -1 mg Activity 16 +MTSEA -1 14 +cocaine 12 10 C 8 5-HT Influx, pmol min 6 4 2 0 c-myc pRSTag C109A I172C res-FLAG sens-myc construct

  26. anti-myc IP myc IP total + - + + + res-FLAG + + + VSV-G sens-myc sens-myc - + + + + VSV-G SERT anti-FLAG anti-VSV-G Streptavidin extract Depleted res-FLAG + + + + sens-myc + - + - 68 kD

  27. X X X Sens-myc Res-FLAG + Sens-myc Res-FLAG + Sens-myc + Cocaine Res-FLAG n o D N A 0 . 0 0 . 2 0 . 4 0 . 6 0 . 8 1 . 0 1 2 5 b [ I ] - C I T b o u n d , f m o l / m g

  28. 10 8 6 Activity, pmol min-1 4 2 80 100 40 60 0 20 percentsensitive

  29. 1.4 1.2 1.0 0.8 Remaining Activity 0.6 0.4 0.2 0.0 0 20 40 60 80 100 Percent Sensitive

  30. Where is the substrate binding site?

  31. 4 2 3 5 6 7 8 9 1 0 1 1 1 2 1 W T B i n d i n g T r a n s p o r t E L 2 b + c o n s e r v e d + ’ + v a r i a n t E L 2 b E L 2 a

  32. 1.4 G484C E494C V488C L491C T497C 1.2 1.0 0.8 0.6 0.4 0.2 0.0 .001 .01 0.1 1 10 100 1.4 A486C L492C V489C Y495C 1.2 1.0 Activity, fraction remaining 0.8 0.6 0.4 0.2 0.0 1.4 Y487C T490C E493C A496C 1.2 1.0 0.8 0.6 0.4 0.2 0.0 1E-4 0.01 0.1 1 10 100 .001 .01 0.1 1 10 100 1E-4 0.01 0.1 1 10 100 .001 .01 0.1 1 10 100 [MTSET], mM

  33. Activity, % WT Remaining Activity, % Inactivation Rate 0 40 80 120 0 20 40 60 80 100 0.01 0.1 1 10 100 T480C L481C T482C S483C G484C G485C A486C Y487C V488C V489C T490C L491C L492C E493C E494C Y495C A496C T497C G498C P499C A500C V501C L502C

  34. L A W A I I T N Y Y S A I Y F A I I C I A “Gate” residue Binding site residues

  35. Not protected. Modification does not block b-CIT binding. Accessibility sensitive to ion and ligand binding. Occluded in NET upon NE translocation. L A W A I Functional, inactivated by MTS reagents. Protected against inactivation by 5-HT and cocaine. Modification prevents b-CIT binding. I T N Y Conserved, required for transport. Cys supports low affinity binding. Y S A I Y F A Labeled from outside, reduced from cytoplasm. I I C I A

  36. L A W A I I T N Y Y S A I Y F A I I C I A “Gate” residue Binding site residues

  37. C109 outside W103 hSERT N101 D98 Y95 inside I172, Y176, I179 N C Residue MTS sensitivity Ligand selectivity Trp-103 -EA, -ET, -ES Asn-101 -EA, -ET Asp-98 -EA, -ET, -ES Gramine-5HT Tyr-95 Mazindol-Citalopram Tryptamine deravitives

  38. Conformational changes

More Related